agilon health (AGL) turned in another unprofitable stretch, with losses accelerating at an average annual rate of 7.9% over the last five years and net profit margins showing no signs of improvement. While the company is forecast to remain in the red through at least the next three years, revenue is expected to grow 10.62% per year, edging out the broader US market's 10.5% annual growth rate. Value investors may be drawn to AGL’s discounted share price and notably low 0.1x price-to-sales multiple compared to industry peers. However, persistent profitability headwinds remain a core concern for the outlook.

See our full analysis for agilon health.

The next section compares these latest results with the most widely followed market narratives, highlighting which storylines hold up and which could face new scrutiny.

See what the community is saying about agilon health

agilon health’s net profit margin remains negative and has not shown improvement, signaling that even as revenues rise, persistent cost pressures weigh on the bottom line.

Consensus narrative points to industry trends and operational investments setting the stage for future profitability. However, ongoing losses reflect a lag in turning growth into stable earnings.

Planned contract enhancements and analytics investments are expected to boost margins and eventually drive positive net income. Yet, medical costs, especially in inpatient and specialty drugs, continue to challenge this transition.

This dynamic means that while recurring revenue and patient growth add stability, achieving the industry-average profit margin of 5.4% remains a significant hurdle for the next few years.

Bulls and bears are both watching whether margin improvement materializes or if rising patient volumes continue to weigh on profitability. ???? Read the full agilon health Consensus Narrative.

While analysts forecast revenue growth of 8.6% annually over the next three years, the reported Medicare Advantage membership contracted from 513,000 to 498,000 year-over-year, highlighting potential revenue concentration risks.

Analysts' consensus view emphasizes that demographic tailwinds and growing demand for value-based care can drive long-term market share gains. However, a highly selective growth approach and potential further attrition in covered lives could stall topline expansion.

With 50% of membership contracts set for renegotiation in 2026, future revenue is exposed to payer dynamics and incremental patient volume loss.

Failing to address risk adjustment revenue declines and execute successful expansion could limit operating leverage and stall the growth narrative.

With the current share price at $0.75, agilon health trades at just 0.1x price-to-sales, a sharp discount to peers (5.4x average), and far below its DCF fair value of $13.21 per share.

Analysts' consensus narrative suggests that such a wide discount reflects the market’s skepticism about a rapid turnaround but leaves open the potential for significant upside if margin and growth milestones are hit in the coming years.

The analyst target price stands at $1.05, 22.6% above the current share price, underscoring both the upside if execution improves and the risk of being trapped in a value trap if profitability stalls.

This low valuation may attract value-focused investors, but durable margin expansion is required before the discount can close meaningfully versus industry averages.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for agilon health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have a different take on the latest results? You can shape your unique perspective into a narrative in just a few minutes. Do it your way

A great starting point for your agilon health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

agilon health's persistent operating losses, lack of margin recovery, and volatile membership trends make it hard to count on reliable, consistent performance in the near future.

If steady growth and predictability are your priorities, use our stable growth stocks screener (2074 results) to uncover companies demonstrating resilient revenue and earnings momentum across market cycles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include AGL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com